Venous thrombosis in children with acute lymphoblastic leukaemia

Česká verze

Authors: L. Cingrošová ¹; K. Zdráhalová, (ČHS) ¹; L. Šrámková ¹; M. Suková ¹; I. Hadačová ²; D. Procházková ³; J. Starý ¹
Authors place of work: Klinika dětské hematologie a onkologie, 2. LF UK a FN Motol, Praha ¹; Oddělení klinické hematologie, FN Motol, Praha ²; Dětská klinka IPVZ, Masarykova nemocnice v Ústí nad Labem, Krajská zdravotní a. s. ³
Published in the journal: Transfuze Hematol. dnes,18, 2012, No. 1, p. 19-24.
Category: Souhrnné práce, původní práce, kazuistiky

Summary

In 2005-2010, six patients (3.9%) out of total 154 children treated for acute lymphoblastic leukaemia developed symptomatic venous thrombosis. Venous thrombosis occurred in 4 cases during induction, once during re-induction and once after the 4^th block of chemotherapy for ALL relapse. Out of the 38 patients who received preventive anticoagulant treatment, 2 (5.3%) developed venous thrombosis. In all cases of venous thrombosis, a combination of risk factors such as central venous line, corticosteroids and L-asparaginase was present. Inherited thrombogenic risk factors did not appear to represent relevant risk factors for venous thrombosis in this group of children with acute lymphoblastic leukaemia treated at our centre. Our data correspond to those relating to deep venous thrombosis cited in literature and their incidence is typical for the induction phase of ALL treatment.

Key words:
acute lymphoblastic leukaemia in children, deep venous thrombosis, genetic risk factors of thrombosis

Zdroje

1. Nowak-Göttl U, Kenet G, Mitchell LG. Thrombosis in childhood acute lymphoblastic leukaemia: epidemiology, aetiology, diagnosis, prevention and treatment. Best Pract Res Clin Haematol 2009; 22(1): 103–114.

2. Payne JH, Vora AJ. Thrombosis and acute lymphoblastic leukaemia. Br J Haematol 2007; 138(4): 430–445.

3. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108 : 2216–2222.

4. Skinner R, Koller K, Pizer B. Prevention and management of central venous catheter occlusion and thrombosis in children with cancer. Pediatr Blood Cancer 2008; 50 : 826–830.

5. Molinari AC, Castagnola E, Mazzola C, et al. Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Support Care Cancer 2001; 9(7): 539–544.

6. Monagle P, Chan A, Massicotte P, et al. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126(3 Suppl): 645S–687S.

7. Monagle P, Chalmers E, Chan A, et al. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133(6 Suppl): 887S–968S.

8. Mitchell L, Lambers M, Flege S, et al. Validation of a predictive model for identifying an increased risk for thromboembolism in children with acute lymphoblastic leukemia: results of a multicenter cohort study. Blood 2010; 115(24): 4999–5004.

9. Nowak-Göttl U, Heinecke A, von Kries R, et al. Thrombotic events revisited in children with acute lymphoblastic leukemia. Impact of concomitant Escherichia coli asparaginase/prednisone administration. Thromb Res 2001; 103 : 165–172.

10. Nowak-Göttl U, Ahlke E, Fleishack G, et al. Thromboembolic events in children with acute lymphoblastic leukemia: prednisone versus dexamethasone administration. Blood 2003; 101(7): 2529–2533.

11. Nowak-Göttl U, Wermes C, Junker R, et al. Prospective evaluation of the thrombotic risk in children with acute lymphoblastic leukemia carrying the MTHFR TT 677 genotype, the prothrombin G20210A variant, and further prothrombotic risk factors. Blood 1999; 93(5): 1595–1599.

12. Male C, Chait P, Andrew M, et al. Central venous line-related thrombosis in children: association with central venous line location and insertion technique. Blood 2003; 101(11): 4273–4278.

13. Molinari AC, Castagnola E, Mazzola C, et al. Thromboembolic complications related to indwelling central venous catheters in children with oncological/haematological diseases: a retrospective study of 362 catheters. Support Care Cancer 2001; 9(7): 539–544.

14. Chalmers E, Ganesen V, Liesner R, et al. Guideline on the investigation, management and prevention of venous thrombosis in children. Br J Haematol 2011; 154(2): 196–207.

15. Korte W, Greiner J, Feldges A, Riesen WF. Increased Lipoproptein(a) levels are not a steady prothrombotic defect. Blood 2001; 98(6): 1993–1994.

16. Blom HJ. Genetic determinants of hyperhomocysteinaemia: the roles of cystathionine beta-synthase and 5,10-methylenetetrahydrofolate reductase. Eur J Pediatr 2000; 159(Suppl 3): S208–S212.

17. Key NS, McGlennen RC. Hyperhomocyst(e)inemia and Thrombophilia. Arch Pathol Lab Med 2002; 126(11): 1367–1375.

18. Athale UH, Siciliano SA, Crowther M, Barr RD, Chan AK. Thromboembolism in children with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute protocols: effect of age and risk stratification of disease. Br J Haematol 2005; 129(6): 803–810.

19. Appel IM, Hop WC, van Kessel-Bakvis C, Stigter R, Pieters R. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia. Thromb Haemost 2008; 100(2): 330–337.